Angtuo
昂拓生物
Angtuo (昂拓生物, also known as Arnatar) is a nucleic acid drug developer founded in 2022 by a team of top global scientists in the field . The company focuses on novel antisense nucleic acid technology and RNA-targeted drug R&D, and has built a proprietary dual-modal platform called DARGER™ . In April 2024, Angtuo raised over $50 million in Series A financing led by investors including Eight Roads, 3E Bioventures Capital, Huajin Capital, Gaorong Ventures, and LYFE Capital, with proceeds earmarked for accelerating pipeline expansion and clinical trials . Gaorong Ventures, which participated in that round, highlighted Angtuo's work on antisense upregulation technology as opening a new chapter in RNA therapeutics .
AI-generated — may contain errors, please verify.
Coverage
Small Nucleic Acid Drugs Enter a New Era, Onto Bio: Pioneering Antisense Upregulation Technology Opens a New Chapter in Cures | Gaorong Future
Moving from "symptomatic treatment" to "disease-modifying therapy."
Rongbao | Multiple autonomous driving, nuclear fusion, gaming, and innovative drug companies raise hundreds of millions of RMB in funding
From commercial deployment to world-first breakthroughs, innovation never stands still.
Rongbao | Major Acquisition in Innovative Drugs; Laser Chips, Quantum Computing, and Global Payment Platform Secure New Funding
"Every step forward feels like a bloom."
Onto Innovation Completes Over $50 Million Series A Financing to Accelerate Deep Pipeline Expansion in Nucleic Acid Drugs
Focused on drug development based on antisense oligonucleotide technology.
